(NASDAQ: VNDA) Vanda Pharmaceuticals's forecast annual revenue growth rate of 23.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 43.71%, and while it is forecast to beat the US market's average forecast revenue growth rate of 15.28%.
Vanda Pharmaceuticals's revenue in 2026 is $215,721,000.On average, 6 Wall Street analysts forecast VNDA's revenue for 2026 to be $15,329,105,035, with the lowest VNDA revenue forecast at $14,235,335,027, and the highest VNDA revenue forecast at $16,620,588,029. On average, 6 Wall Street analysts forecast VNDA's revenue for 2027 to be $20,785,257,910, with the lowest VNDA revenue forecast at $18,072,297,144, and the highest VNDA revenue forecast at $23,489,753,900.
In 2028, VNDA is forecast to generate $23,971,641,515 in revenue, with the lowest revenue forecast at $21,864,516,873 and the highest revenue forecast at $25,711,757,647.